Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 1,018 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,018 shares of Stoke Therapeutics stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $30.87, for a total transaction of $31,425.66. Following the completion of the transaction, the general counsel directly owned 24,594 shares of the company’s stock, valued at approximately $759,216.78. This trade represents a 3.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jonathan Allan also recently made the following trade(s):

• On Friday, December 5th, Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.29, for a total transaction of $274,882.65.
• On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total value of $70,249.80.
• On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.78, for a total value of $68,017.52.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.07, for a total value of $250,700.00.

Stoke Therapeutics Trading Down 0.6%

Shares of NASDAQ STOK opened at $30.87 on Friday. The company has a market capitalization of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $38.69. The stock has a 50 day moving average of $29.03 and a 200-day moving average of $19.83.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. Analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on STOK shares. Needham & Company LLC raised their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Chardan Capital upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $31.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co raised its position in shares of Stoke Therapeutics by 12.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock valued at $296,000 after buying an additional 1,313 shares in the last quarter. Polar Capital Holdings Plc increased its stake in Stoke Therapeutics by 49.8% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after acquiring an additional 439,824 shares during the period. Parkman Healthcare Partners LLC bought a new position in Stoke Therapeutics during the 3rd quarter worth $5,875,000. Nomura Holdings Inc. acquired a new position in Stoke Therapeutics in the 3rd quarter valued at $1,908,000. Finally, Millennium Management LLC lifted its position in shares of Stoke Therapeutics by 199.3% during the 3rd quarter. Millennium Management LLC now owns 61,048 shares of the company’s stock valued at $1,435,000 after acquiring an additional 40,652 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.